Inventiva S.A. Halts Trading for Financing
- Trading Halt: Inventiva S.A. requested a halt in trading of its ordinary shares on Euronext Paris starting June 2, 2026, to prepare for an upcoming financing transaction, indicating the company's urgency in raising capital.
- Resumption Timing: Trading is expected to resume later that same day at approximately 3:30 p.m. CEST, coinciding with the anticipated start of ADS trading on the Nasdaq under ticker 'IVA', highlighting the company's active presence in international markets.
- Clinical Trial Progress: Inventiva is advancing its novel pan-PPAR agonist Lanifibranor in the pivotal Phase 3 NATiV3 trial for adult patients with MASH, showcasing the company's potential in addressing metabolic dysfunction-associated liver diseases.
- Stock Price Fluctuation: Over the past year, Inventiva's stock has fluctuated between $2.85 and $7.98, closing at $4.77 on Monday, down 3.25%, reflecting market caution regarding the company's future financing and clinical developments.
Trade with 70% Backtested Accuracy
Analyst Views on IVA
About IVA
About the author
Inventiva S.A. Halts Trading for Financing
- Trading Halt: Inventiva S.A. requested a halt in trading of its ordinary shares on Euronext Paris starting June 2, 2026, to prepare for an upcoming financing transaction, indicating the company's urgency in raising capital.
- Resumption Timing: Trading is expected to resume later that same day at approximately 3:30 p.m. CEST, coinciding with the anticipated start of ADS trading on the Nasdaq under ticker 'IVA', highlighting the company's active presence in international markets.
- Clinical Trial Progress: Inventiva is advancing its novel pan-PPAR agonist Lanifibranor in the pivotal Phase 3 NATiV3 trial for adult patients with MASH, showcasing the company's potential in addressing metabolic dysfunction-associated liver diseases.
- Stock Price Fluctuation: Over the past year, Inventiva's stock has fluctuated between $2.85 and $7.98, closing at $4.77 on Monday, down 3.25%, reflecting market caution regarding the company's future financing and clinical developments.
Inventiva S.A. Reports No Revenue for Q1 2026
- No Revenue Recognition: Inventiva S.A. reported no revenue for Q1 2026, mirroring the performance of Q1 2025, indicating ongoing challenges in revenue growth that may affect investor confidence.
- Stable Cash Position: As of Q1 2026, the company held €75.0 million in cash and cash equivalents, along with €121.5 million in short-term deposits, maintaining relatively healthy liquidity despite cash outflows, which supports future R&D activities.
- Impact of R&D Spending: The net cash used was primarily due to the company's planned operating activities related to its lanifibranor development program, suggesting that while Inventiva is advancing its core product, it may face short-term financial pressure that could impact market performance.
- Uncertain Market Outlook: Although the company's investment in R&D may lay the groundwork for future growth, the current lack of recognized revenue raises concerns about its long-term profitability, potentially affecting stock performance.
Inventiva S.A. Reports FY GAAP EPS and Revenue Decline
- Financial Performance Decline: Inventiva S.A. reported a FY GAAP EPS of -€1.90, indicating significant challenges in profitability and reflecting ongoing financial pressures on the company.
- Revenue Plummet: The reported revenue of €4.5M represents a 51.0% year-over-year decline, which could adversely affect the company's future investment attractiveness and market confidence.
- Market Reaction Anticipation: Given the poor financial data, investors may adopt a cautious stance towards Inventiva S.A.'s future performance, potentially leading to stock price volatility and diminished market confidence.
- Industry Conference Participation: Despite facing challenges, Inventiva S.A. actively participated in the Barclays 28th Annual Global Healthcare Conference and the 44th Annual J.P. Morgan Healthcare Conference, demonstrating its ongoing presence in the industry and intent to seek financing opportunities.
Tilray Brands, SuperX AI Technology, and Other Major Stocks Decline in Friday's Pre-Market Trading
U.S. Stock Futures: U.S. stock futures rose this morning, with Dow futures increasing by approximately 50 points on Friday.
Tilray Brands Inc: Shares of Tilray Brands Inc fell 15% in pre-market trading after announcing a one-for-10 reverse stock split, set to take effect on December 1.
Other Stocks Declining: Several other stocks also experienced declines in pre-market trading, including Inventiva ADR (-7.4%), Anglogold Ashanti PLC (-5.5%), and Lexicon Pharmaceuticals Inc (-5%).
Market Movements: SuperX AI Technology Ltd saw a significant drop of 3.9% after a previous surge, while Gold Fields Ltd and Abacus Global Management Inc also reported declines following recent gains.
Heartbeam Shares Surge Approximately 43%; Check Out 20 Stocks Making Moves in Premarket Trading
Heartbeam Inc's Stock Surge: Heartbeam Inc's shares rose 43.3% in pre-market trading after announcing its regulatory strategy following the FDA's Not Substantially Equivalent decision on its Electrocardiogram Synthesis Software, with plans for an appeal or 510(k) resubmission.
Other Notable Gainers: Several stocks saw significant gains in pre-market trading, including SMX PLC (+73.1%), Zenta Group (+26.7%), and Waton Financial (+21.1%), reflecting a positive trend in the market.
Major Losers: FBS Global Ltd experienced a sharp decline of 24.3%, while Tilray Brands fell 15% after announcing a reverse stock split, indicating volatility among certain stocks.
Market Overview: The pre-market trading session showed mixed results, with notable gains for some companies and significant losses for others, highlighting the fluctuating nature of the stock market.
Inventiva's Shareholders' Meeting Approves All Resolutions Except for the 5th One
- Shareholder Meeting Outcome: During the shareholders' meeting on November 27, 2025, all resolutions were approved except for the 5th, indicating strong shareholder support for the company's governance and future strategic direction.
- Voting Participation: A total of 441 shareholders participated, representing 56.432% of the voting rights, highlighting shareholder engagement and enhancing the company's transparency in the capital market.
- 5th Resolution Rejected: The 5th resolution was rejected with only 41.642% support, reflecting shareholders' cautious stance towards the board's proposal, which may impact the company's future capital structure and employee incentive plans.
- CEO Compensation Policy Approved: The shareholders unanimously approved the CEO's compensation policy, demonstrating trust in management, which could help attract and retain key talent to drive the company's growth.
Inventiva S.A. Halts Trading for Financing
- Trading Halt: Inventiva S.A. requested a halt in trading of its ordinary shares on Euronext Paris starting June 2, 2026, to prepare for an upcoming financing transaction, indicating the company's urgency in raising capital.
- Resumption Timing: Trading is expected to resume later that same day at approximately 3:30 p.m. CEST, coinciding with the anticipated start of ADS trading on the Nasdaq under ticker 'IVA', highlighting the company's active presence in international markets.
- Clinical Trial Progress: Inventiva is advancing its novel pan-PPAR agonist Lanifibranor in the pivotal Phase 3 NATiV3 trial for adult patients with MASH, showcasing the company's potential in addressing metabolic dysfunction-associated liver diseases.
- Stock Price Fluctuation: Over the past year, Inventiva's stock has fluctuated between $2.85 and $7.98, closing at $4.77 on Monday, down 3.25%, reflecting market caution regarding the company's future financing and clinical developments.
Inventiva S.A. Reports No Revenue for Q1 2026
- No Revenue Recognition: Inventiva S.A. reported no revenue for Q1 2026, mirroring the performance of Q1 2025, indicating ongoing challenges in revenue growth that may affect investor confidence.
- Stable Cash Position: As of Q1 2026, the company held €75.0 million in cash and cash equivalents, along with €121.5 million in short-term deposits, maintaining relatively healthy liquidity despite cash outflows, which supports future R&D activities.
- Impact of R&D Spending: The net cash used was primarily due to the company's planned operating activities related to its lanifibranor development program, suggesting that while Inventiva is advancing its core product, it may face short-term financial pressure that could impact market performance.
- Uncertain Market Outlook: Although the company's investment in R&D may lay the groundwork for future growth, the current lack of recognized revenue raises concerns about its long-term profitability, potentially affecting stock performance.
Inventiva S.A. Reports FY GAAP EPS and Revenue Decline
- Financial Performance Decline: Inventiva S.A. reported a FY GAAP EPS of -€1.90, indicating significant challenges in profitability and reflecting ongoing financial pressures on the company.
- Revenue Plummet: The reported revenue of €4.5M represents a 51.0% year-over-year decline, which could adversely affect the company's future investment attractiveness and market confidence.
- Market Reaction Anticipation: Given the poor financial data, investors may adopt a cautious stance towards Inventiva S.A.'s future performance, potentially leading to stock price volatility and diminished market confidence.
- Industry Conference Participation: Despite facing challenges, Inventiva S.A. actively participated in the Barclays 28th Annual Global Healthcare Conference and the 44th Annual J.P. Morgan Healthcare Conference, demonstrating its ongoing presence in the industry and intent to seek financing opportunities.
Tilray Brands, SuperX AI Technology, and Other Major Stocks Decline in Friday's Pre-Market Trading
U.S. Stock Futures: U.S. stock futures rose this morning, with Dow futures increasing by approximately 50 points on Friday.
Tilray Brands Inc: Shares of Tilray Brands Inc fell 15% in pre-market trading after announcing a one-for-10 reverse stock split, set to take effect on December 1.
Other Stocks Declining: Several other stocks also experienced declines in pre-market trading, including Inventiva ADR (-7.4%), Anglogold Ashanti PLC (-5.5%), and Lexicon Pharmaceuticals Inc (-5%).
Market Movements: SuperX AI Technology Ltd saw a significant drop of 3.9% after a previous surge, while Gold Fields Ltd and Abacus Global Management Inc also reported declines following recent gains.
Heartbeam Shares Surge Approximately 43%; Check Out 20 Stocks Making Moves in Premarket Trading
Heartbeam Inc's Stock Surge: Heartbeam Inc's shares rose 43.3% in pre-market trading after announcing its regulatory strategy following the FDA's Not Substantially Equivalent decision on its Electrocardiogram Synthesis Software, with plans for an appeal or 510(k) resubmission.
Other Notable Gainers: Several stocks saw significant gains in pre-market trading, including SMX PLC (+73.1%), Zenta Group (+26.7%), and Waton Financial (+21.1%), reflecting a positive trend in the market.
Major Losers: FBS Global Ltd experienced a sharp decline of 24.3%, while Tilray Brands fell 15% after announcing a reverse stock split, indicating volatility among certain stocks.
Market Overview: The pre-market trading session showed mixed results, with notable gains for some companies and significant losses for others, highlighting the fluctuating nature of the stock market.
Inventiva's Shareholders' Meeting Approves All Resolutions Except for the 5th One
- Shareholder Meeting Outcome: During the shareholders' meeting on November 27, 2025, all resolutions were approved except for the 5th, indicating strong shareholder support for the company's governance and future strategic direction.
- Voting Participation: A total of 441 shareholders participated, representing 56.432% of the voting rights, highlighting shareholder engagement and enhancing the company's transparency in the capital market.
- 5th Resolution Rejected: The 5th resolution was rejected with only 41.642% support, reflecting shareholders' cautious stance towards the board's proposal, which may impact the company's future capital structure and employee incentive plans.
- CEO Compensation Policy Approved: The shareholders unanimously approved the CEO's compensation policy, demonstrating trust in management, which could help attract and retain key talent to drive the company's growth.
